Rapamycin: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
==Structure== | ==Structure== | ||
<StructureSection load='' size='340' side='right' caption='' scene='82/821566/Rapamycin/ | <StructureSection load='' size='340' side='right' caption='' scene='82/821566/Rapamycin/3'> | ||
[[Image:Rapamycin.png]] | [[Image:Rapamycin.png]] | ||
Rapamycin, a macrolide, has a <scene name='82/821566/Rapamycin/ | Rapamycin, a macrolide, has a <scene name='82/821566/Rapamycin/3'>cyclic structure</scene>. It <scene name='82/821566/Rapamycin/2'>binds to the regulator protein mTORC1</scene> with the help of another protein called FKBP52<ref>PMID: 23358420</ref> | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Latest revision as of 14:27, 17 July 2019
Rapamycin, isolated from the bacterium Streptomyces hygroscopicus, is an immuno-suppressant and anticancer drug[1]. It acts by binding the the mTORC1 protein complex, a kinase that regulates cell growth and metabolism. In the future, it might also be used in treatment of type 2 diabetes[2].
Structure
| |||||||||||
